EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Correlation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D

Marlene Hintersteininger, Michael Schwarz, Philipp Schwabl, Lukas Hartl iD, Lorenz Balcar iD, Benedikt Silvester Hofer iD, Georg Kramer iD, Christian Sebesta iD, Paul Thöne, Patrik Attalla, Michael Gschwantler, Michael Trauner und 3 weitere

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Marlene Hintersteininger und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Bile Acids and Salts, Antiviral Agents, Lipopeptides, Hepatitis D. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bulevirtide (BLV) blocks hepatitis D virus (HDV) entry by targeting the sodium taurocholate co‐transporting polypeptide (NTCP). This study assessed the relationship between bile acid (BA) levels and antiviral response to BLV.

Methods

Serum BA levels were monitored in HDV‐infected patients pre‐, under, and post BLV treatment. Virologic response (VR) was defined by ≥ 2log 10 decline in HDV‐RNA and discriminated versus virologic non‐response (VNR). Delta BA levels (ΔBA) were calculated and analysed in relation to HDV‐RNA dynamics. Finally, the effect of BLV treatment cessation on BA was investigated.

Results

Twenty five patients (48% male; advanced chronic liver disease [ACLD]: 92.0%, 17 patients with VR at W48) were included. Median baseline BA levels were significantly higher in patients with ACLD and portal hypertension ( n = 10; 19.2 vs. 5.1 μmol/L; p = 0.015). No difference in median on‐treatment BA levels was detected between patients achieving VR or VNR at W24 (VR: 25.4 vs. VNR: 22.7 μmol/L; p = 1.000) and W48 (VR: 25.4 vs. VNR: 20.8 μmol/L; p = 1.000). Additionally, ΔBA from baseline to W48 did not differ between VR and VNR ( p = 0.534). No significant association between ΔBA and HDV‐RNA dynamics at W48 was detected. After BLV discontinuation, median BA levels significantly dropped to normal ranges (18.9 μmol/L at last on‐BLV assessment to 7.6 μmol/L after discontinuation; p = 0.028). On‐treatment BA levels did neither associate with self‐reported compliance nor with treatment‐related adverse events.

Conclusion

Bulevirtide increases bile acid levels in most patients, but ΔBA does not predict virologic response or adverse events, nor does it reflect compliance to therapy. Bile acid level monitoring during and following bulevirtide treatment is thus, not advised for clinical practise.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bile Acids and SaltsAntiviral AgentsLipopeptidesHepatitis DHumansMaleMiddle AgedFemaleAdultHepatitis Delta VirusRNA, ViralSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

bile acidsbulevirtidechronic hepatitis Dvirologic response

Substanzen

Bile Acids and SaltsAntiviral AgentsbulevirtideRNA, ViralLipopeptides

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine II, University Hospital of Sankt Pölten, Sankt Pölten, Austria.
  • Department of Internal Medicine IV, Klinik Ottakring, Vienna, Austria.

ORCID-Profile: Lukas Hartl, Lorenz Balcar, Benedikt Silvester Hofer, Georg Kramer, Christian Sebesta, Mattias Mandorfer, Thomas Reiberger, Mathias Jachs

Zitieren

APA

Hintersteininger, M., Schwarz, M., Schwabl, P., Hartl, L., Balcar, L., Hofer, B. S., Kramer, G., Sebesta, C., Thöne, P., Attalla, P., Gschwantler, M., Trauner, M., Mandorfer, M., Reiberger, T., & Jachs, M. (2026). Correlation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70675

Vancouver

Hintersteininger M, Schwarz M, Schwabl P, Hartl L, Balcar L, Hofer BS, et al. Correlation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70675

BibTeX
@article{Hintersteininger2026,
  author = {Hintersteininger, Marlene and Schwarz, Michael and Schwabl, Philipp and Hartl, Lukas and Balcar, Lorenz and Hofer, Benedikt Silvester and Kramer, Georg and Sebesta, Christian and Thöne, Paul and Attalla, Patrik and Gschwantler, Michael and Trauner, Michael and Mandorfer, Mattias and Reiberger, Thomas and Jachs, Mathias},
  title = {Correlation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70675}
}
Kostenlos starten →